Published in J Am Acad Dermatol on November 01, 1984
Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol (2011) 0.82
Rosacea. Pathophysiology and treatment. Arch Dermatol (1994) 2.86
The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol (1980) 1.76
Azelaic acid esters do not depigment pigmented guinea pig skin. Arch Dermatol (1990) 1.37
Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol (1999) 1.37
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis (1999) 1.35
Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem (2000) 1.33
Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem (1992) 1.28
Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J Biol Chem (1997) 1.17
Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun (1991) 1.15
Unilateral dermatomal superficial telangiectasia. Nine new cases and a review of unilateral dermatomal superficial telangiectasia. J Am Acad Dermatol (1983) 1.10
Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther (1985) 1.05
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem (1993) 1.05
Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther (1982) 1.03
Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med (1994) 0.97
Flushing reactions: consequences and mechanisms. Ann Intern Med (1981) 0.97
Evidence against an acyl-enzyme intermediate in the reaction catalyzed by clostridial phosphotransacetylase. Biochemistry (1976) 0.96
Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood (1996) 0.95
Molluscum contagiosum venereum in a women's outpatient clinic: a venereally transmitted disease. Am J Obstet Gynecol (1977) 0.94
Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood (1990) 0.93
Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry (1994) 0.91
An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun (1990) 0.91
Actinic keratoses. Am Fam Physician (1984) 0.90
Synthesis and biological evaluation of neutral derivatives of 5-fluoro-2'-deoxyuridine 5'-phosphate. J Med Chem (1983) 0.90
Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol (1981) 0.89
Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost (1992) 0.89
Characterization of urokinase receptor expression by human placental trophoblasts. Blood (1992) 0.89
Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate (1998) 0.89
Eczema herpeticum in association with familial benign chronic pemphigus. J Am Acad Dermatol (1993) 0.88
Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer (1995) 0.88
Comparison of model and nuclear magnetic resonance structures for the human inflammatory protein C5a. Proteins (1988) 0.88
Serum and synovial fluid levels of serum amyloid A protein and C-reactive protein in inflammatory and noninflammatory arthritis. J Rheumatol (1988) 0.87
Nodular colloid degeneration: distinctive histochemical and ultrastructural features. Cutis (1985) 0.87
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem (1990) 0.87
Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol (1985) 0.86
Rosacea. Int J Dermatol (1983) 0.86
Pityriasis rosea-like rash from captopril. Arch Dermatol (1982) 0.86
Reactive perforating collagenosis of diabetes mellitus and renal failure. Cutis (1983) 0.86
Iododerma occurring during thyroid protection treatment. Cutis (1985) 0.86
Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res (1997) 0.86
Unilateral dermatomal superficial telangiectasia. Dermatologica (1978) 0.85
Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Thromb Res (1988) 0.84
Thermal stability of low molecular weight urokinase during heat treatment. II. Effect of polymeric additives. Pharm Res (1994) 0.84
Sequence-specific assignments in the 1H NMR spectrum of the human inflammatory protein C5a. Biochemistry (1988) 0.84
Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer (1993) 0.84
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. J Med Chem (1990) 0.83
Treatment of leishmaniasis with sodium antimony gluconate: transient ECG findings. South Med J (1978) 0.82
Isotope, pulse-chase, stopped-flow, and rapid quench studies on the kinetic mechanism of bovine dihydropteridine reductase. Biochemistry (1984) 0.82
Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. J Vet Intern Med (2012) 0.82
Failure of drug rash to appear in a previously irradiated site. Arch Dermatol (1981) 0.82
gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. J Cell Sci (1995) 0.82
Bier's spots reconsidered: a tale of two spots, with speculation on a humerus vein. J Am Acad Dermatol (1986) 0.82
Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin). Eur J Biochem (1997) 0.81
Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J Biol Chem (2000) 0.81
Vascular abnormalities in lichen aureus. J Am Acad Dermatol (1983) 0.80
Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem (1995) 0.80
Uterine adenocarcinoma metastatic to the skin responsive to megestrol acetate. J Dermatol Surg Oncol (1994) 0.80
A quantitative, non-invasive method for the characterization of flushing reactions. J Invest Dermatol (1982) 0.80
Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol (1997) 0.80
Diethylstilbestrol (DES) quinone: a reactive intermediate in DES metabolism. Biochem Pharmacol (1983) 0.79
Domain structure and interactions of recombinant urokinase-type plasminogen activator. J Biol Chem (1992) 0.79
Comparative localization of receptors for plasmin and for urokinase on MCF 7 cells. Exp Cell Res (1993) 0.78
The menopausal queen: adjustment to aging and the male homosexual. Am J Orthopsychiatry (1973) 0.78
Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol (1983) 0.78
An unusual case of calcinosis cutis. J Am Acad Dermatol (1983) 0.78
Soluble human urokinase receptor is composed of two active units. J Biol Chem (1997) 0.78
Periodic cutaneous blood flow during postocclusive reactive hyperemia. Am J Physiol (1986) 0.78
Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure (2000) 0.78
Cutaneous reactions to lower aliphatic alcohols before and during disulfiram therapy. Arch Dermatol (1982) 0.77
Substrate specificity of human cutaneous alcohol dehydrogenase and erythema provoked by lower aliphatic alcohols. J Invest Dermatol (1987) 0.77
Optimizing the bolus/infusion ratio for intravenous administration of urokinase in dogs. Thromb Res (1988) 0.77
Exogenous rh-urokinase modifies inflammation and Pseudomonas aeruginosa infection in a rat chronic pulmonary infection model. Can J Microbiol (1993) 0.76
The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase. Thromb Haemost (1992) 0.76
Quantitative assessment of alcohol-provoked flushing. Arch Dermatol (1986) 0.76
Acquired persistent erythematous patch on the neck. Acquired nevus flammeus. Arch Dermatol (1994) 0.76
Perilesional heparin injections for necrobiosis lipoidica. J Am Acad Dermatol (1983) 0.76
Ethnic contact urticaria to alcohol. Contact Dermatitis (1985) 0.76
Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator. J Biol Chem (1993) 0.76
Cutaneous vascular sensitivity to lower aliphatic alcohols and aldehydes in Orientals. Alcohol Clin Exp Res (1985) 0.76
Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem J (1992) 0.75
Characterization of the activation of pro-urokinase by thermolysin. Biochim Biophys Acta (1993) 0.75
Pruritus in sickle cell disease: response to cholestyramine. J Natl Med Assoc (1977) 0.75
Re: chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol (2000) 0.75
Use of topical products for maintaining remission in rosacea. Arch Dermatol (1999) 0.75
Potential subversion of pregnancy prevention program in the managed care setting. Arch Dermatol (1997) 0.75
Blockade of carcinoid flush with cimetidine and clonidine. Arch Dermatol (1982) 0.75
Diaper dermatitis. Am Fam Physician (1982) 0.75
Vascular factors and the localization of varicella lesions. J Am Acad Dermatol (1981) 0.75
Periorbital hyperpigmentation. JAMA (1981) 0.75
The role of mononitrochlorobenzene as a contaminant in dinitrochlorobenzene. J Am Acad Dermatol (1982) 0.75
Letter: Facial flushing is not blushing. N Engl J Med (1976) 0.75
Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model. Thromb Res (1996) 0.75
Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model. Thromb Haemost (1997) 0.75
Scarification treatment of granuloma annulare. Arch Dermatol (1982) 0.75
Unilateral dermatomal cavernous hemangiomatosis. Dermatologica (1980) 0.75
Unilateral nevoid telangiectasia: three new cases and the role of estrogen. Arch Dermatol (1977) 0.75
Acanthoma fissuratum cutis. Report of a case and a review of previous cases. J Dermatol Surg Oncol (1978) 0.75